(Q24245782)

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

1 reference

7 January 2021

Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001100.PUB2

7 January 2021

10.1002/14651858.CD001100.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15495007

1 reference

Consolidated OpenCitations Corpus – April 2017